Keywords
Last Name
Institution

Kimo Stine

TitleProfessor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentPediatrics, College of Medicine
DivisionPeds Hematology
Address ACH Sturgis Building
800 Marshall Street
Mail Slot # 512-10
Little Rock AR 72202
Phone501-364-1494
vCardDownload vCard

    Collapse Research Funds 
    Collapse principal investigator
    Pass Through Agency: PSI Pharma Support America, Inc - Funding Agency: BioMarin Pharmaceutical Inc. - Title: Global Prospective Laboratory Study for Adenovirus-Associated Virus Seroprevalence in Hemophilia A Patients with Residual Factor VIII Levels <2IU/dL Who Were Previously Treated with Factor VIII - Start Date: 2017-09-01

    Pass Through Agency: PSI Pharma Support America, Inc - Funding Agency: - Title: A Phase 1/2, Open-label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 in Adult Subjects with Severe Hemophilia A - Start Date: 2017-07-01

    Pass Through Agency: PPD Development, LP - Funding Agency: Dimension Therapeutics - Title: A Long-Term Follow-up Study to Evaluate the Safety, Tolerability, and Efficacy of Adeno-Associated Virus (AAV) rh10-Mediated Gene Transfer of Human Factor IX in Adults with Moderate/Severe to Severe Hemophilia B - Start Date: 2017-07-01

    Pass Through Agency: St. Jude Children's Research Hosptial - Funding Agency: Histiocytosis Association - Title: LCH-IV: International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis - Start Date: 2016-11-01

    Funding Agency: Cookies for Kids Cancer - Title: Phase II Study of Clofarabine in Refractory Langerhans Cell Histiocytosis- LCH-CLO - Start Date: 2016-01-01

    Pass Through Agency: PPD Development, LP - Funding Agency: Dimension Therapeutics - Title: A Phase 1/2 Open-Label Dose-Finding Study of Adeno-Associated Virus rh10-Mediated Gene Transfer of Human Factor IX in Adults with Moderate/Severe to Severe Hemophilia B - Start Date: 2015-11-23

    Funding Agency: Bioverativ, Inc - Title: An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein in the Prevention and Treatment of Bleeding in Previously Untreated Patients with Severe Hemophilia A - Start Date: 2015-09-24

    Pass Through Agency: American Thrombosis and Hemostasis Network - Funding Agency: Biogen Idec Inc. - Title: My Life, Our Future: A Hemophilia Genotyping Initiative Data and Sample Research Repository - Start Date: 2015-09-01

    Funding Agency: - Title: Consortium for Clinical and Translational Research in Langerhans Cell Histiocytosis (LCH) - Start Date: 2014-07-01

    Pass Through Agency: Atlantic Research Group, Inc - Funding Agency: Green Cross Corp - Title: An open label Safety and Efficacy extension study of GreenGene F in Previously Treated Patients Diagnosed with Severe Hemophilia A - Start Date: 2013-11-01

    Pass Through Agency: University of Texas - Funding Agency: Centers for Disease Control - Title: Region VI TX Subcontract CDC-Community Counts: Public Health Surveillance for Bleeding Disorders - Start Date: 2013-09-30

    Funding Agency: Boston Medical Center - Title: ICON 1: Physician Treatment Decisions and Patient-Reported Outcomes in Pediatric Refractory Immune Thrombocytopenia - Start Date: 2013-09-01

    Funding Agency: Baxter - Title: A Phase 2/3 Multi-Center, Open Label Study of Efficacy, Safety and PK of PEGylated Recombinant Factor VIII Administered for Prophylaxis and Treatment of Bleeding in Previously Treated Patients with Severe Hemophilia A - Start Date: 2013-03-01

    Funding Agency: Bayer Inc. - Title: A Multi-Center, Phase III, non-controlled, open-label trial to evaluate the pharmacokinetics, safety, and efficacy of BAY 94-9027 for prophylaxis and treatment of bleeding in previously treated children (age < 12 years) with severe hemophilia A - Start Date: 2013-03-01

    Funding Agency: UAMS ACHRI Flow Through - Title: Program for Bleeding Disorders and Thrombosis in Arkansas (ACHRI # 037028) - Award Number: ACHRI # 037028 - Total direct costs: $78,955 - Start Date: 2013-01-01

    Funding Agency: Bayer Inc. - Title: A Phase II/III, multicenter, partially randomized, open label trial investigating safety and efficacy of on-demand and prophylactic treatment with BAY 94-9027 in Severe Hemophilia A - Start Date: 2012-12-04

    Funding Agency: Green Cross Corp - Title: Determination of Safety, Efficacy adn PK of GreenGene F in Previously Treated Patients 12YO or older Diagnosed with Severe Hemophilia A. - Start Date: 2012-10-01

    Pass Through Agency: University of Texas - Funding Agency: Centers for Disease Control - Title: Prevention of the Complications of Hemophilia Through Hemophilia Treatment Centers (subcontract with UT) - Start Date: 2012-09-30

    Funding Agency: CSL Behring L.L.C. - Title: A Pilot Study to Examine the Effect of Extracorporeal Membrane Oxygenation (ECMO) on Plasma Factor XIII Levels Relative to other Circulating Factors - Start Date: 2012-05-01

    Funding Agency: American Thrombosis & Hemostasis Network - Title: ATHN Data Quality Counts Funding Continuation Rounds 4.1 - Start Date: 2012-02-01


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Neunert C, Despotovic J, Haley K, Lambert MP, Nottage K, Shimano K, Bennett C, Klaassen R, Stine K, Thompson A, Pastore Y, Brown T, Forbes PW, Grace RF. Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study. Pediatr Blood Cancer. 2016 08; 63(8):1407-13. PMID: 27135461.
      View in: PubMed
    2. Stine KC, Wahl EC, Liu L, Skinner RA, VanderSchilden J, Bunn RC, Montgomery CO, Aronson J, Becton DL, Nicholas RW, Swearingen CJ, Suva LJ, Lumpkin CK. Nutlin-3 treatment spares cisplatin-induced inhibition of bone healing while maintaining osteosarcoma toxicity. J Orthop Res. 2016 Oct; 34(10):1716-1724. PMID: 26867804.
      View in: PubMed
    3. Stieglitz E, Taylor-Weiner AN, Chang TY, Gelston LC, Wang YD, Mazor T, Esquivel E, Yu A, Seepo S, Olsen SR, Rosenberg M, Archambeault SL, Abusin G, Beckman K, Brown PA, Briones M, Carcamo B, Cooper T, Dahl GV, Emanuel PD, Fluchel MN, Goyal RK, Hayashi RJ, Hitzler J, Hugge C, Liu YL, Messinger YH, Mahoney DH, Monteleone P, Nemecek ER, Roehrs PA, Schore RJ, Stine KC, Takemoto CM, Toretsky JA, Costello JF, Olshen AB, Stewart C, Li Y, Ma J, Gerbing RB, Alonzo TA, Getz G, Gruber TA, Golub TR, Stegmaier K, Loh ML. Corrigendum: The genomic landscape of juvenile myelomonocytic leukemia. Nat Genet. 2016 Jan; 48(1):101. PMID: 26711114.
      View in: PubMed
    4. Stine KC. Risk organ + LCH gets the one-two punch? Blood. 2015 Sep 17; 126(12):1399-400. PMID: 26384280.
      View in: PubMed
    5. Minoia F, Davì S, Horne A, Bovis F, Demirkaya E, Akikusa J, Ayaz NA, Al-Mayouf SM, Barone P, Bica B, Bolt I, Breda L, De Cunto C, Enciso S, Gallizzi R, Griffin T, Hennon T, Horneff G, Jeng M, Kapovic AM, Lipton JM, Magni Manzoni S, Rumba-Rozenfelde I, Magalhaes CS, Sewairi WM, Stine KC, Vougiouka O, Weaver LK, Davidsone Z, De Inocencio J, Ioseliani M, Lattanzi B, Tezer H, Buoncompagni A, Picco P, Ruperto N, Martini A, Cron RQ, Ravelli A. Dissecting the heterogeneity of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Rheumatol. 2015 Jun; 42(6):994-1001. PMID: 25877504.
      View in: PubMed
    6. Bussel JB, Hsieh L, Buchanan GR, Stine K, Kalpatthi R, Gnarra DJ, Ho RH, Nie K, Eisen M. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP). Pediatr Blood Cancer. 2015 Feb; 62(2):208-213. PMID: 25345874.
      View in: PubMed
    7. Pasala S, Fiser RT, Stine KC, Swearingen CJ, Prodhan P. von Willebrand factor multimers in pediatric extracorporeal membrane oxygenation support. ASAIO J. 2014 Jul-Aug; 60(4):419-23. PMID: 24727537.
      View in: PubMed
    8. Stine KC, Wahl EC, Liu L, Skinner RA, Vanderschilden J, Bunn RC, Montgomery CO, Suva LJ, Aronson J, Becton DL, Nicholas RW, Swearingen CJ, Lumpkin CK. Cisplatin inhibits bone healing during distraction osteogenesis. J Orthop Res. 2014 Mar; 32(3):464-70. PMID: 24259375; PMCID: PMC4080883.
    9. Lane J, McLaren PJ, Dorrell L, Shianna KV, Stemke A, Pelak K, Moore S, Oldenburg J, Alvarez-Roman MT, Angelillo-Scherrer A, Boehlen F, Bolton-Maggs PH, Brand B, Brown D, Chiang E, Cid-Haro AR, Clotet B, Collins P, Colombo S, Dalmau J, Fogarty P, Giangrande P, Gringeri A, Iyer R, Katsarou O, Kempton C, Kuriakose P, Lin J, Makris M, Manco-Johnson M, Tsakiris DA, Martinez-Picado J, Mauser-Bunschoten E, Neff A, Oka S, Oyesiku L, Parra R, Peter-Salonen K, Powell J, Recht M, Shapiro A, Stine K, Talks K, Telenti A, Wilde J, Yee TT, Wolinsky SM, Martinson J, Hussain SK, Bream JH, Jacobson LP, Carrington M, Goedert JJ, Haynes BF, McMichael AJ, Goldstein DB, Fellay J. A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A. Hum Mol Genet. 2013 May 01; 22(9):1903-10. PMID: 23372042; PMCID: PMC3613165.
    10. Lane, Jerome, Dorrel, Luch, Shianna, Kevin, Stemke, Amanda, Pelak, Kimberly, Moore, Stephen, Albert, Thilo, Alvarez-Roman, M.T., Angelillo-Scherrer, Anne, Barrett, John, Boehlen, Francoise, Bolton-Maggs, Paula, Brand, Brigit, Brown, Deborah, Chiang, Elaine, Cid-Haro, Ana, Collins, Peter, Eyster, M. Elaine, Fogarty, Patrick, Giangrande, Paul, Gringeri, Alessandro, Iyer, Rathi, Katsarou, Olga, Kempton, Christine, Kuriakose, Philip, Lin, Judith, Makris, Mike, Manco-Johnson, Marilyn, Marbet, German, Martinez-Picado, Javier, Mauser-Bunschoten, Evelien, Neff, Anne, Oka, Shinichi, Oyesiku, Lara, Parra, Rafael, Peter-Salonen, Kristiina, Powell, Jerry, Recht, Michael, Shapiro, Amy, Stine, Kimo, Talks, Ktherine, Telenti, Amalio, Wilde, Jonathan, Yee, Thynn Thynn, Wolinsky, Steven, Martinson, Jeremy, Detels, Roger, Margolick, Joseph, Jacobson, Lisa, Carrington, Mary, Goedert, James, Haynes, Barton, McMichael, Andrew, Goldstein, David, Jellay, Jacques. A genome-wide association study of resistance to HIV infection in highly exposed uninfected individiuals with hemophilia A. 2013.
    11. Warren, Bryce A., Stine K. PILOT PROGRAM TO DEVELOP REMOTE DATA VERIFICATION OF PATIENTS ENROLLED ON LCH-IV. 2012.
    12. Grace RF, Bennett CM, Ritchey AK, Jeng M, Thornburg CD, Lambert MP, Neier M, Recht M, Kumar M, Blanchette V, Klaassen RJ, Buchanan GR, Kurth MH, Nugent DJ, Thompson AA, Stine K, Kalish LA, Neufeld EJ. Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia. Pediatr Blood Cancer. 2012 Feb; 58(2):221-5. PMID: 21674758; PMCID: PMC3863944.
    13. Nugent, D, Bussel, J, Buchanan,G, Stine K, Kalpathi, R, Nie, K, Eisen, M. Longer-term use of the thrombopoietin-mimetic peptibody romiplostim in children with chronic/refractory immune thrombocytopenia (ITP): results of an open label extension study. Pediatric Blood and Cancer. 2011; 916.
    14. Grace, RF, Neufeld, EJ, Ritchey, AK, Kumar, M, Jeng, MR, Blanchette, V, Klassen, R, Buchanan, GR, Heisel Kurth, MA, Nugent, DJ, Thompson, AA, Thornburg, C, Lambert, MP, Neier, MD, Recht, M, Stine K, Kalish, LA, Bennet, C. The North American Chronic Immune Thrombocytopenia Registry (NACIR): Demographics and Treatment Responses. 2011.
    15. Grace, RF, Neufeld, EJ, Ritchey, AK, Kumar, M, Jeng, MR, Blanchette, V, Klaassen, R, Buchanan, GR, Kurth, MAH, Nugent, DJ, Thompson, AA, Thornburg, C, Lambert, MP, Neier, MD, Recht, M, Stine K, Kalish, LA, Bennett, CM. The North American Chronic Immune Thrombocytopenia REgistry (NACIR): Demographics and treatment responses. Blood. 2010; 1039-1040.
    16. Jeha S, Razzouk B, Rytting M, Rheingold S, Albano E, Kadota R, Luchtman-Jones L, Bomgaars L, Gaynon P, Goldman S, Ritchey K, Arceci R, Altman A, Stine K, Steinherz L, Steinherz P. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Oncol. 2009 Sep 10; 27(26):4392-7. PMID: 19652076; PMCID: PMC2744276.
    17. Stine KC, Becton DL. Bleeding disorders: when is normal bleeding not normal? J Ark Med Soc. 2009 Aug; 106(2):40-2. PMID: 19715248.
      View in: PubMed
    18. Schmitz MA, St. Amour E, Chang MM, Stine K, Austen MA, Jo CH, Killebrew P, Jaquiss R. Baseline Thromboelastography Reference Ranges for Infants and Children Presenting for Elective Cardiac Surgery. Pediatric Blood & Cancer. 2009; 179.
    19. Schmitz Michael A, St. Amour Edgar, Chang MM, Stine K, Austen MA, Jo CH, Killebrew P, Jaquiss R. Baseline Thromboelastography Reference Ranges for Infants and Children Presenting for Elective Cardiac Surgery. 2009.
    20. Schmitz ML, St. Amour ED, Stine K, Austen MA, Jo C, Killebrew P, Jaquiss RJ. Effects of angiotensin-converting enzyme inhibition on thromboelastography for infants and children presenting for elective cardiac surgery. Blood. 2009; 446.
    21. Nicholas, Richard W., Stine KC. Sarcomas of the Bone in Children, Adolescents, and young Adults. Pediatric Commentary. 2009; 17(2):16-17.
    22. Schmitz ML, St. Amour ED, Stine K, Austen MA, Jo Chanhee, Killebrew P, Jaquiss RJ. Effects of Angiotensin-Converting Enzyme Inhibition on Thromboelastography for infants and Children Presenting for Elective Cardiac Surgery. 2008.
    23. O'Brien MM, Taub JW, Chang MN, Massey GV, Stine KC, Raimondi SC, Becton D, Ravindranath Y, Dahl GV. Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421. J Clin Oncol. 2008 Jan 20; 26(3):414-20. PMID: 18202418; PMCID: PMC3897300.
    24. Becton D., Buckmiller L, Vincent K, Stine KC. Successful tretament of Kaposiform Hemangioendothelioma with Vincristine-based therapy. 21st Annual Meeting of the American Society of Pediatric Hematology Oncology. 2008; 47.
    25. Stine KC, Shrum D, Becton DL. Use of FEIBA for invasive or surgical procedures in patients with severe hemophilia A or B with inhibitors. J Pediatr Hematol Oncol. 2007 Apr; 29(4):216-21. PMID: 17414562.
      View in: PubMed
    26. Stine KC, Saylors RL, Saccente CS, Becton DL. Treatment of deep vein thrombosis with enoxaparin in pediatric cancer patients receiving chemotherapy. Clin Appl Thromb Hemost. 2007 Apr; 13(2):161-5. PMID: 17456625.
      View in: PubMed
    27. Williams T, Stine KC, Walker PD, Ilyas M, Wang Y, Blaszak RT. Clinical quiz. A patient with hyperuricemia and renal failure. Pediatr Nephrol. 2007 Jul; 22(7):948-53. PMID: 17384967.
      View in: PubMed
    28. Saylors R, Saccente S, Becton D, Stine KC. Asymptomatic involvement of the thyroid gland by Langerhan's Cell Histiocytosis in a pediatric patient. Pediatric Blood and Cancer. 2007; 754.
    29. Stine KC, Becton DL. Use of factor VIII replacement during open heart surgery in a patient with haemophilia A. Haemophilia. 2006 Jul; 12(4):435-6. PMID: 16834747.
      View in: PubMed
    30. Ullah S, Schmitz ML, Stine KC, Johnson CE, Faulkner SC, Drummond-Webb JJ. Post-cardiopulmonary bypass coagulopathy in a neonate with a family history of von Willebrand disease. J Cardiothorac Vasc Anesth. 2006 Aug; 20(4):576-9. PMID: 16884994.
      View in: PubMed
    31. Bernstein ML, Devidas M, Lafreniere D, Souid AK, Meyers PA, Gebhardt M, Stine K, Nicholas R, Perlman EJ, Dubowy R, Wainer IW, Dickman PS, Link MP, Goorin A, Grier HE. Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--a report from the Children's Oncology Group. J Clin Oncol. 2006 Jan 01; 24(1):152-9. PMID: 16382125.
      View in: PubMed
    32. Stine KC, Becton D, Dahl G, Ravindranth Y, Raimondi S, Behm F, Chang M, Arceci R. TBI and allogeneic BMT do not appear to hinder growth in pediatirc patients with AML treated on POG 9421. American Society of Hematology. 2006; 3677.
    33. O'Brien M, Taub J, Stine KC, Chang M, Ravindranath Y, Becton D, Dahl G. Excessive Cardiotoxicity despite excellent leukemia-free survival for pediatric patients with Down Syndrome (DS) and Acute Myeloid Leukemia (AML). American Society of Hematology. 2006; 559.
    34. Bernstein M, Devidas M, Lafreniere D, Souid A-K, Meyers P, Gebhardt M, Stine KC, Nicholas R, Perlman E, Dubowy R, Wainer I, Link M, Goorin A, Grier H. Intensive therapy with growth factor support for patients with Ewing's Tumor metastatic at diagnosis, POG/CCG Phase II study 9457. JCO. 2006; 24:152-159.
    35. Becton D, Dahl GV, Ravindranath Y, Chang MN, Behm FG, Raimondi SC, Head DR, Stine KC, Lacayo NJ, Sikic BI, Arceci RJ, Weinstein H. Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. Blood. 2006 Feb 15; 107(4):1315-24. PMID: 16254147; PMCID: PMC1895393.
    36. Stine KC, Westfall C. Sinus histiocytosis with massive lymphadenopathy (SHML) prednisone resistant but dexamethasone sensitive. Pediatr Blood Cancer. 2005 Jan; 44(1):92-4. PMID: 15390291.
      View in: PubMed
    37. Stine KC, Becton D, Shrum D. Use of FEIBA for Surgical Procedures in Patients With Severe Hemophilia A and B and Inhibitors. International Society of Thrombosis and Hemostasis. 2005; p246.
    38. Kraut EH, Aledort LM, Arkin S, Stine KC, Wong W-Y. Surgical Procedures in Patients With Inhibitors To Factor VIII: A Case Series. International Society of Thrombosis and Hemostasis. 2005; 1143.
    39. Stine KC, Saylors RL, Saccente S, McClain KL, Becton DL. Efficacy of continuous infusion 2-CDA (cladribine) in pediatric patients with Langerhans cell histiocytosis. Pediatr Blood Cancer. 2004 Jul; 43(1):81-4. PMID: 15170896.
      View in: PubMed
    40. Stine KC, Shrum D, Becton DL. Use of FEIBA for surgical procedures in patients with severe Hemophilia A and inhibitors. World Federation of Hemophilia. 2004.
    41. Stine KC, Becton D, Dahl GVH, Ravindranth Y, Raimondi S, Behm FG, Chang M, Weinstein H. Genetic Randomization to allogeneic bone marrow transplant in first remission pediatric acute myeloid leukemia patients, Pediatric Oncology Group 9421 (now Childrens Oncology Group). American Society of Hematology. 2004; 178a.
    42. Buchanan G, Adix L, Dlaassen R, Neufeld E, Zimmerman S, Stine KC. Quantitiative Assessment of Drug Treatment side effects in Children with Idiopathic Thrombocytopenic Purpura (ITP). American Society of Hematology. 2004; 828a.
    43. Stine KC, Saylors RL, Saccente S, Becton DL. Long-term survival in osteosarcoma patients following retinoblastoma using doxorubicin, cisplatin, and methotrexate. Med Pediatr Oncol. 2003 Jul; 41(1):77-8. PMID: 12764753.
      View in: PubMed
    44. Stine KC, Saylors RL, Saccente S, Becton D. 2-Chlorodeoxyadenosine (2-CDA) for the treatment of refractory or recurrent Langerhan’s Cell Histiocytosis in pediatric patients. XIX Annual Meeting of the Histiocyte Society. 2003.
    45. Parham DM, Ready R, Stine K, Quiggins C, Becton D, North P. Comparison of manual and automated leukocyte counts for determination of the absolute neutrophil count: application to a pediatric oncology clinic. Med Pediatr Oncol. 2002 Mar; 38(3):183-6. PMID: 11836718.
      View in: PubMed
    46. Stine KC, Warren BA, Becton DL. IL-12 induces IL-12 Receptor (R) up-regulation in Ewing’s Sarcoma Cell lines prior to apoptosis. Pediatric Academic Societies. 2002.
    47. Stine KC, Warren BA, Saylors RL, Becton DL. IL-12 induces IL-12 Receptor (IL-12R) expression in sensitive AML cell lines. Pediatric Academic Society. 2002; 1359.
    48. McClure GYH, Helm RM, Stine KC, Burks AW, Jones SM, Gandy J. Evaluation of the immune parameters in propanil exposed farm families. Arch. Environ. Contam. Toxicol. 2001; 41:104-111.
    49. Stine KC, Warren BA, Saylors RL, Becton DL. IL-12 induces IL-12 receptor (IL-12R) expression on IL-12 sensitive cell lines. American Society of Hematology. 2001; 4609.
    50. Becton DL, Ravindranath Y, Dahl GV, Berkow RL, Chang M, Stine KC, Behm FG, Raimondi SC, Massey G, Weinstein HJ. A Phase III Study of Intensive Cytarabine (ARA-C) Induction followed by cyclosporine (CSA) modulation of Drug Resistance in De Novo Pediatric AML: POG 9421. 43rd Annual American Society of Hematology. 2001; 1929.
    51. Bernstein Mark L, Goorin Allen, Devidas Meenakshi, Lafreniere Dominique, Stine KC, Meyers Paul, Grier Holcombe. Topotecan and Topotecan, cyclophosphamide window therapy in ptaients (PTS) with Ewing Sarcoma (EWS) metastatic at diagnosis: an Intergroup Pediatric Oncology Group (POG) Study (P-9457). International Society of Paediatric Oncology (SIOP) XXXIII Meeting. 2001; 176.
    52. Schexnayder S, Stine KC. Illustrated Textbook of Pediatric Emergency and Critical Care Procedures. Blood Components and Transfusions. 2000.
    53. Saylors RL, Stine KC, Sullivan J, Bernstein M, Harris MB. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a pediatric oncology group(POG) phase II study. American Society of Pediatric Hematology Oncology. 1999; 465.
    54. Stine KC, Saylors RL, Becton DL. 2-Chlorodeoxyadenosine (2-CDA)for the treatment of refractory or recurrent Langerhan’s histiocytosis in pediatric patients. American Society of Pediatric Hematology Oncology. 1999; 450.
    55. NL Siebel, J Parentesis, Stine KC, RC Trueworthy, J Weinthal, S Weitman, MA Cox, CM Baum, MN Needle. PHASE I STUDY OF LERIDISTIM IN PEDIATRIC PATIENTS TREATED WITH ICE CHEMOTHERAPY. American Society of Hematology. 1999; 48a.
    56. Parham DM, North P, Quiggins C, Ready R, Stine KC, Becton D. Comparison of manual vs. automated leukocyte counts for determination of the absolute neutrophil count. American Society of Pediatric Hematology Oncology. 1999; 52.
    57. Ogden AK, Hurwitz C, Becton D, Stine KC. Combination therapy with Idarubicin (IDA) and Cladribine (CDA) in pediatric patients with relapsed and refractory acute myeloid leukemia (AML). American Society of Clinical Oncology. 1997; 1870.
    58. Stine KC, Becton DL, Warren, BA, Weinstein H, Behm F. IL-2 and IL-12 augment apoptosis of cryopreserved pediatric AML blasts. American Society of Hematology. 1997; 1235.
    59. McClure GYH, Helm RM, Stine KC, Burks AW, Jones SM, Gandy J. Evaluation of the immune parameters in propanil exposed farm families. 1997; 1343.
    60. Schexnayder S, Stine KC. Illustrated Textbook of Pediatric Emergency and Critical Care Procedures. Blood Components and Transfusions. 1997.
    61. Stine KC, Warren BA, Becton DL. Apoptosis induced by IL-12 measured by DNA electrophoresis and in situ end labeling in leukemia. Proceedings of New York Academy of Sciences Symposium on Interleukin 12: Cellular and molecular immunolgy of an important regulatory cytokine. 1995.
    62. Stine KC, Warren B, Becton DL. IL-12 mediates apoptosis of KG1a, U937, but not K562, or HL-60 cell lines. American Society of Clinical Oncology. 1995.
    63. Stine KC, Warren BA, Becton DL. Apoptosis induced by IL-6 or IL-12 measured by DNA electrophoresis and in situ end labeling in leukemia. American Society of Hematology. 1995; 743a.
    64. Stine KC, Williams L, Saylors RL, Becton DL. 2-Cholorodeoxyadenosine (2-CDA) for the treatment of refractory or recurrent Langerhans's Histiocytosis in pediatric patients. 37th Annual Meeting of the American Society of Hematology. 1995; 510a.
    65. Kletzel M, Abella S, Sandler E, Ogden A, Stine KC, Shenoy S, Wall DA. Thiotepa/cyclophosphamide with autologous marrow rescue for advanced stage neuroblastoma: Preliminary analysis fails to demonstrate efficacy of involved field radiation therapy or purging. 1994.
    66. Stine KC, Warren B., Becton D. In vitro effects of Interleukin-12 on acute non-lymphocytic leukemia. 1994; 200.
    67. Stewart E, Rasco C, Cincotta NF, Pawletko TM, Stine KC. Multidisciplinary rounds. Case study: acute lymphocytic leukemia. Cancer Pract. 1993; 1(2):94 - 97.
    68. Schexnayder SM, Stine KC, Webster PA, Heulitt MJ, Becton DL. A technique for automated exchange transfusion in children and young adults. 1993; 783A.
    69. Hults C., Stine KC, Longee D, Becton D. Prospective analysis of IL-6 levels in patients (PT) with hemophilia. 1993; 730A.
    70. Haut, Paul R, Schutze, Gordon E, Stine KC, Becton, David L. Use of varicella zoster immune globulin in immunocompromised patients. 1993; 41 (4): 734A.
    71. Stine KC, Hults C. P24 binds to activated lymphocytes and other cell lines. 1993; 797A.
    72. Klasner A, Longee D, Stine KC, Becton D. Deficiency of vitamin K-dependent coagulation factors. 1993; 803A.
    73. Stine KC, Tyler DS, Stanley SD, Bartlett JA, Bolognesi DP, Weinhold KJ. The effect of AZT on in vitro lymphokine-activated killer (LAK) activity in human immunodeficiency virus type-1 (HIV-1) infected individuals. Cell Immunol. 1991; 136(1):165 - 172.
    74. Stine KC, Garry, R.F. Regulation of NK activity by p24. Fourth International Conference On Human Retrovirology: HTLV. 1991.
    75. Stine KC, Falletta JM. Current Practive of Interventional Radiology. Intra-arterial chemotherapy of osteosarcoma and soft tissue sarcomas. 1991.
    76. Kirkpatrick, Dahlia V, Barrios, Nilka J, O'Byrne, Cathy, Regueira, Osvaldo, McNeil, Judy, Singleton, Frank, Stine KC. Bone marrow transplantation in childhood nasopharyngeal carcinoma. American Pediatric Society/Society for Pediatric Research. 1991; 29: 845.
    77. Gomez, Luisa M, Van Dyke, Russell B, Alchediak, Thomas, Stine KC. CD4 and CD8 lymphocyte profiles in uninfected infants born to HIV-1 infected mothers. American Pediatric Society/Society for Pediatric Research. 1991; 92:923.
    78. Regureir, Osvaldo, Barrios, Nilda J, Humbert, James R, Stine KC. Medulloblastoma and rhabdoid tumor of the kidney, a case report. American Pediatric Society/Society for Pediatric Research. 1991; 29: 876.
    79. Stine KC. Description of a receptor for p24 on the cell surface of interleukin-2 activated lymphocyte. AACR. 1991; 32:A1677.
    80. Tyler DS, Stanley SD, Nastala CA, Austin AA, Bartlett JA, Stine KC, Lyerly HK, Bolognesi DP, Weinhold KJ. Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects. J Immunol. 1990; 144(9):3375 - 3384.
    81. Barrios NJ, Kirkpatrick DV, Murciano A, Stine KC, Van Dyke RB, Humbert JR. Successful treatment of disseminated Fusarium infection in an immunocompromised child. Am J Pediatr Hemat-Oncol. 1990; 12:319-324.
    82. Barrios NJ, Kirkpatrick DV, Stine KC, Humbert JR. Lithium therapy in Fanconi aplastic anaemia. Br J Haematol. 1989; 73(3):422 - 423.
    83. Tyler, D., Stanley, S.D., Nastala, C., Stine KC, Bolognesi, D, Weinhold, K. Anti-HIV antibody directed cytotoxicity: Cellular and Humoral defects. Vth International Confer¬ence on AIDS. 1989.
    84. Stine KC, Friedman HS, Kurtzberg J, Filston HC, Baker ME, Lowe J, Falletta JM. Pulmonary septic emboli mimicking metastatic rhabdomyosarcoma. J Pediatr Surg. 1989; 24(5):491 - 493.
    85. David, S.S., Miller, N., Stine KC, Tyler, D., Bolognesi, D., Weinhold, K. HIV-1 infected monocytes as a target for ADCC. Fifth International Conference on AIDS. 1989; 512.
    86. Barrios, N, Kirkpatrick, D, Stine KC, McNeil, J., Humbert, J. Use of cyclosporine A (CSA) in Shwachman-Diamond (SD) syndrome. ASH 31st Annual Meeting. 1989.
    87. Barrios, N., Stine KC, Kirkpatrick, D., Jones, M., Humbert, J. Emergency treatment of severe immune thrombocytopenia (ITP) with a combination of high dose IV steroids and immunoglobulins (IG). ASH 31 st Annual Meeting. 1989.
    88. Kirkpatrick, D., Barrios, N., Stine KC, Stern, M., Scott, W. A pilot study of outpatient ceftriaxone treatment for fever in children over 2 years of age with sickle cell disease. ASH 31st Annual Meeting,. 1989.
    89. Weinhold KJ, Lyerly HK, Matthews TJ, Tyler DS, Ahearne PM, Stine KC, Langlois AJ, Durack DT, Bolognesi DP. Cellular anti-GP120 cytolytic reactivities in HIV-1 seropositive individuals. Lancet. 1988; 1(8591):902 - 905.
    90. Stine KC, Tyler, D.S., Stanley, S.D., Bolognesi, D.P., Weinhold, K.J. Ex vivo activation of cellular cytotoxic re¬sponses in HIV-1 infected patients. Society of Biological Therapy. 1988.
    91. Kurtzberg JK, Friedman HS, Kinney TR, Chaffee S, Stine KC, Falletta JM, Weinhold KJ. Management of human immunodeficiency virus-associated thrombocytopenia with intravenous gamma globulin. Am J Pediatr Hemat-Oncol. 1987; 9:299-301.
    92. Stine KC, Linshaw, M. A. Response to furosemide in hyperkalemic renal tubular acidosis (RTA). SPR. 1984; 364a.
    93. Tyler, D.S., Nastala, C.L., Stine KC, Bartlett, J., Bolognesi, D.P., Lyerly, H.K., Weinhold, K.J. Therapeutic applica¬tions of Interleukin-2 augmentation of HIV-1 specific cellular immune reactivity.
    94. Stine KC, Tyler, D., Stanley S., Bartlett J, Bolognesi D., Weinhold, K. Lymphokine activated killer (LAK) activity in asymptomatic HIV-1 seropositive patients (PT). ASH 31 st Annual Meeting.
    95. Barrios, NJ, Alchediak, T, Kirkpatrick, DV, Stine KC, Paulus, A, Andes, A. Response to high dose steroids, IV immunoglobulins (IVIG) and lithium in a patient with HIV-1 infection and bone marrow aplasia. Third Annual Meeting of the American Society of Pediatric Hematology/Oncology.
    96. Kirkpatrick, D., Barrios, N., Stine KC, Varela, M., Humbert, J. Transient expression of trisomy 21 and monosomy 7 following cyclosporine A (CSA) in a patient with aplastic anemia. ASH 31st Annual Meeting. 1989.
    97. Stanley, S.D, Miller N, Stine KC, Tyler D., Bolognesi D., Weinhold K. HIV-1 infected Monocytes as a target for ADCC. Vth International Conference on AIDS.
    98. Sherman A, Poling T, Simonton S, Faucett J, Wheeler G, Stine KC. Immune changes in healthy subjects: A comparison of relaxation, imagery and meditation. Annual Conference of American Psychosomatic Society.
    99. Stine KC, Garry, Robert A. HIV-1 core protein interaction with human lymphocytes. American Pediatric Society/Society for Pediatric Research.
    Stine's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _